107
Participants
Start Date
July 2, 2010
Primary Completion Date
February 11, 2014
Study Completion Date
December 19, 2016
Immunotherapeutic GSK2302025A, different formulations
Intramuscular administration
GSK Investigational Site, Marseille
GSK Investigational Site, Berlin
GSK Investigational Site, Genoa
GSK Investigational Site, Rozzano (MI)
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Lübeck
GSK Investigational Site, Kiel
GSK Investigational Site, Hanover
GSK Investigational Site, Bordeaux
GSK Investigational Site, Rennes
GSK Investigational Site, Nantes
GSK Investigational Site, Essen
GSK Investigational Site, Meldola (FC)
GSK Investigational Site, Rimini
GSK Investigational Site, Ravenna
GSK Investigational Site, Reims
GSK Investigational Site, Vandœuvre-lès-Nancy
GSK Investigational Site, Mainz
GSK Investigational Site, Lille
GSK Investigational Site, Homburg
GSK Investigational Site, Mannheim
GSK Investigational Site, Tübingen
GSK Investigational Site, Napoli
GSK Investigational Site, Nuremberg
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Pyatigorsk
GSK Investigational Site, Chelyabinsk
GSK Investigational Site, Brno
GSK Investigational Site, Hradec Králové
GSK Investigational Site, Prague
GSK Investigational Site, Jena
GSK Investigational Site, Gdansk
GSK Investigational Site, Poznan
GSK Investigational Site, Słupsk
GSK Investigational Site, Saint Petersburg
Lead Sponsor
GlaxoSmithKline
INDUSTRY